FDA Clears Abbott's Genetic FISH Panel for Leukemia Patient Prognosis

Abbott ABT announced today it has received 510k clearance from the U.S. Food and Drug Administration for a new in vitro diagnostic test to aid in determining the prognosis of patients with chronic lymphocytic leukemia, a cancer of the lymphocytes. Abbott's Vysis CLL FISH Probe Kit is the first FDA-cleared CLL test to aid in prognosis. The test detects genetic abnormalities in lymphocytes. Lymphocytes, a type of white blood cell, help the body fight infection. In CLL, abnormal lymphocytes are